{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"3"},{"groupId":"OG001","value":"2"},{"groupId":"OG002","value":"1"},{"groupId":"OG003","value":"4"},{"groupId":"OG004","value":"1"},{"groupId":"OG005","value":"0"},{"groupId":"OG006","value":"1"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"3"},{"groupId":"OG001","value":"2"},{"groupId":"OG002","value":"1"},{"groupId":"OG003","value":"4"},{"groupId":"OG004","value":"1"},{"groupId":"OG005","value":"3"},{"groupId":"OG006","value":"1"}],"units":"Participants"}],"description":"To assess the safety and tolerability of AUTO4 administration. The incidence of Grade 3-5 toxicities occurring within 60 days of AUTO4 infusion.","groups":[{"description":"Patients received 25x10\\^6 RQR8/aTRBC1 CAR T-positive cells","id":"OG000","title":"Phase I Dose Escalation - Cohort 1"},{"description":"Patients received 75x10\\^6 RQR8/aTRBC1 CAR T-positive cells","id":"OG001","title":"Phase I Dose Escalation - Cohort 2"},{"description":"Patients received 225x10\\^6 RQR8/aTRBC1 CAR T-positive cells","id":"OG002","title":"Phase I Dose Escalation - Cohort 3"},{"description":"Patients received 450x10\\^6 RQR8/aTRBC1 CAR T-positive cells","id":"OG003","title":"Phase I Dose Escalation - Cohort 4"},{"description":"Patients received 225x10\\^6 RQR8/aTRBC1 CAR T-positive cells","id":"OG004","title":"Phase I Dose Escalation With Modified Manufacturing Process - Cohort 3"},{"description":"Patients received 450x10\\^6 RQR8/aTRBC1 CAR T-positive cells","id":"OG005","title":"Phase I Dose Escalation With Modified Manufacturing Process - Cohort 4"},{"description":"Patients received 900x10\\^6 RQR8/aTRBC1 CAR T-positive cells","id":"OG006","title":"Phase I Dose Escalation With Modified Manufacturing Process - Cohort 5"}],"paramType":"COUNT_OF_PARTICIPANTS","reportingStatus":"POSTED","timeFrame":"60 days of AUTO4 infusion","title":"The Numbers of Patients With Grade 3 to 5 Toxicity Occurring Within 60 Days of AUTO4 Infusion.","type":"PRIMARY","unitOfMeasure":"Participants"}